Skip to content
You are now leaving https://www.ionispharma.com to visit

First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington’s Disease

First of 4+ Ionis programs expected to advance to pivotal studies this year Ionis earns $35 million milestone payment CARLSBAD, Calif. , Jan. 28, 2019 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that its partner Roche , also